Suppr超能文献

肺纤维化的当前认识:发病机制、诊断及治疗方法

Current Understanding of Pulmonary Fibrosis: Pathogenesis, Diagnosis, and Therapeutic Approaches.

作者信息

Cui Dinglu, Che Xiangguo, An Rongxian, Li Lei, Cui Xinying, Jiang Long, Jin Jingchun

机构信息

Department of Rheumatology, Yanbian University Hospital, Yanji, China.

Department of Biochemistry and Cell Biology, Korea Mouse Phenotyping Center, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.

出版信息

Can Respir J. 2025 Jul 15;2025:3183241. doi: 10.1155/carj/3183241. eCollection 2025.

Abstract

Pulmonary fibrosis (PF) is a terminal-stage lung change in interstitial lung disease. It is characterized by proliferation of fibroblasts and deposition of a large amount of extracellular matrix, accompanied by inflammatory damage and structural destruction, caused by various reasons. The prognosis of PF is poor, and the average survival time after diagnosis is 2.5-3.5 years. The pathogenesis of PF is not yet fully understood. Its main mechanisms are diverse and include damage to alveolar epithelial cells, aggregation and activation of inflammatory cells and chemokines, proliferation of fibroblasts, transformation of myofibroblasts, production and deposition of large amounts of collagen, autophagy, epithelial-mesenchymal transition (EMT), mitochondrial quality-control disorders, microRNA, and circular RNA. The diagnosis of PF is mainly based on the comprehensive evaluation of clinical manifestations, imaging characteristics, and histopathological examination. Medical and family history to determine all potential causes of PF. For PF of unknown etiology, one can refer to the Official Clinical Practice Guideline of idiopathic pulmonary fibrosis (IPF) for definitive diagnosis. In terms of treatment, modern medications such as pirfenidone and nintedanib can inhibit the progression of PF to some extent and improve lung function. However, there is no drug that can significantly improve PF, except for lung transplantation. In addition, many patients are forced to stop taking medication due to adverse reactions in clinical practice. Therefore, to better control the progression of disease, some new drugs have been developed based on the pathogenesis of PF. However, there is still controversy over their efficacy and widespread clinical application in PF, and the evidence is limited. The results of in vitro and in vivo experiments, as well as randomized clinical trials, indicate that traditional Chinese medicine (TCM) can improve PF by intervening in multiple pathways and targets. This study combines the pathogenesis and diagnosis of PF, focusing on the intervention mechanism and targets of TCM in the treatment of PF, so as to provide more options for clinical treatment and provide scientific basis for a new approach to better management of PF.

摘要

肺纤维化(PF)是间质性肺疾病的终末期肺部改变。它的特征是成纤维细胞增殖和大量细胞外基质沉积,伴有炎症损伤和结构破坏,由多种原因引起。PF的预后较差,诊断后的平均生存时间为2.5至3.5年。PF的发病机制尚未完全明确。其主要机制多种多样,包括肺泡上皮细胞损伤、炎症细胞和趋化因子的聚集与激活、成纤维细胞增殖、肌成纤维细胞转化、大量胶原蛋白的产生与沉积、自噬、上皮-间质转化(EMT)、线粒体质量控制紊乱、微小RNA和环状RNA。PF的诊断主要基于临床表现、影像学特征和组织病理学检查的综合评估。询问病史和家族史以确定所有可能导致PF的原因。对于病因不明的PF,可参考特发性肺纤维化(IPF)的官方临床实践指南进行明确诊断。在治疗方面,诸如吡非尼酮和尼达尼布等现代药物可在一定程度上抑制PF的进展并改善肺功能。然而,除了肺移植外,尚无药物能显著改善PF。此外,在临床实践中,许多患者因不良反应而被迫停药。因此,为了更好地控制疾病进展,基于PF的发病机制研发了一些新药。然而,它们在PF中的疗效和广泛临床应用仍存在争议,且证据有限。体外和体内实验以及随机临床试验的结果表明,中药可以通过干预多种途径和靶点来改善PF。本研究结合PF的发病机制和诊断,重点关注中药治疗PF的干预机制和靶点,以便为临床治疗提供更多选择,并为更好地管理PF的新方法提供科学依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a30/12283196/4d2f51ff93c7/CRJ2025-3183241.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验